Theriva Biologics Inc

NYSE American:TOVXUnited States

Theriva Biologics, Inc., formerly Synthetic Biologics, Inc., is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of unmet need. The Company is engaged in the development of oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient's immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.

Contact Information

Headquarters

9605 Medical Center Drive, Suite 270ROCKVILLE, MD, United States 20850

Phone

734-332-7800

Fax

734-332-7878

Executives

Independent Chairman of the Board

Jeffrey Kraws

Chief Executive Officer, Chief Financial Officer, Director

Steven Shallcross

Chief Operating Officer

Frank Tufaro

Independent Director

John Monahan

Independent Director

Jeffrey Wolf